Modified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination

Basit Öğe Kaydı
dc.contributor.authorSinani, Genada
dc.contributor.authorSessevmez, Melike
dc.contributor.authorGök, M. Koray
dc.contributor.authorÖzgümüş, Saadet
dc.contributor.authorAlpar, H. Oya
dc.contributor.authorCevher, Erdal
dc.date.accessioned2021-05-15T11:34:18Z
dc.date.available2021-05-15T11:34:18Z
dc.date.issued2019
dc.departmentEczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalıen_US
dc.descriptionOZGUMUS, SAADET/0000-0002-1793-0859; Cevher, Erdal/0000-0002-0486-2252; GOK, MEHMET KORAY/0000-0003-2497-9359
dc.description.abstractNasal vaccination is considered to be an effective and convenient way of increasing immune responses both systemically and locally. Although various nanovaccine carriers have been introduced as potential immune adjuvants, further improvements are still needed before they can be taken to clinical usage. Chitosan-based nanovaccine carriers are one of the most widely studied adjuvants, owing to the ability of chitosan to open tight junctions between nasal epithelial cells and enhance particle uptake as well as its inherent immune activating role. In present study, bovine serum albumin (BSA) loaded nanoparticles were prepared using novel aminated (aChi) and aminated plus thiolated chitosan (atChi) polymers, to further enhance mucoadhesiveness and adjuvanticity of the vaccine system by improving electrostatic interactions of polymers with negatively charged glycoproteins. Nanocarriers with optimum size and surface charge, high encapsulation efficiency of model antigen and good stability were developed. Negligible toxicity was observed in Calu-3 and A549 cell lines. In vivo studies, revealed high levels of systemic antibodies (IgG, IgG(1) and IgG(2a)) throughout the study and presence of sIgA in vaginal washes showed that common mucosal system was successfully stimulated. Cytokine levels indicated a mixed Th1/Th2 immune response. A shift towards cellular immune responses was observed after nasal immunisation with antigen loaded nanoparticle formulations. These nanoparticles exhibit great potential for nasal application of vaccines.en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of Istanbul UniversityIstanbul University [36160]; Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)en_US
dc.description.sponsorshipThis work was supported by Scientific Research Projects Coordination Unit of Istanbul University, No: 36160. Genada Sinani acknowledges The Scientific and Technological Research Council of Turkey (TUBITAK) for the PhD Fellowship Program.en_US
dc.identifier.doi10.1016/j.ijpharm.2019.118592
dc.identifier.issn0378-5173
dc.identifier.issn1873-3476
dc.identifier.pmid31386881
dc.identifier.scopus2-s2.0-85070714461
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.ijpharm.2019.118592
dc.identifier.urihttps://hdl.handle.net/20.500.12939/305
dc.identifier.volume569en_US
dc.identifier.wosWOS:000488123900052
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAlpar, H. Oya
dc.institutionauthorSinani, Genada
dc.language.isoen
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Pharmaceutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNanoparticlesen_US
dc.subjectNasal Deliveryen_US
dc.subjectMucosal Vaccinationen_US
dc.subjectChitosanen_US
dc.subjectAntibodyen_US
dc.subjectCytokineen_US
dc.titleModified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu